Mark Edward Dailey, MD

- In this segment, Dr. Caron A. Jacobson discusses strategies to streamline referrals for chimeric antigen receptor (CAR) T-cell therapy in patients with diffuse large B-cell lymphoma (DLBCL). She emphasizes the importance of understanding how CAR T-cell services are organized at the receiving institution, as referral pathways may differ across centers.

In this segment, Dr. Mark Dailey, Dr. Caron A. Jacobson, and NP Stefanie Sigmund introduce the challenges of coordinating chimeric antigen receptor (CAR) T-cell therapy for patients with diffuse large B-cell lymphoma (DLBCL), particularly those who must travel long distances to specialized treatment centers.